613 related articles for article (PubMed ID: 30383117)
21. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
[TBL] [Abstract][Full Text] [Related]
22. Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam.
Bian B; Gorevski E; Kelton CM; Guo JJ; Martin Boone JE
J Manag Care Pharm; 2012 Sep; 18(7):506-15. PubMed ID: 22971204
[TBL] [Abstract][Full Text] [Related]
23. Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020.
Desai A; Scheckel C; Jensen CJ; Orme J; Williams C; Shah N; Leventakos K; Adjei AA
JAMA Netw Open; 2022 Jan; 5(1):e2144923. PubMed ID: 35076701
[TBL] [Abstract][Full Text] [Related]
24. Generic drugs in dermatology: part II.
Payette M; Grant-Kels JM
J Am Acad Dermatol; 2012 Mar; 66(3):353.e1-15; quiz 367-8. PubMed ID: 22342022
[TBL] [Abstract][Full Text] [Related]
25. Characteristics and Price Increases Among Sole-Source, Off-Patent Drugs in the United States, 2008 to 2018.
Alpern JD; Shahriar AA; Xi M; Thapa S; Kodet AJ; Stauffer WM; Vazquez Benitez G; Pawloski PA; Dehmer SP
JAMA Netw Open; 2020 Aug; 3(8):e2013595. PubMed ID: 32804216
[TBL] [Abstract][Full Text] [Related]
26. High prices for generics in Australia - more competition might help.
Bulfone L
Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
[TBL] [Abstract][Full Text] [Related]
27. Generic drugs in dermatology: part I.
Payette M; Grant-Kels JM
J Am Acad Dermatol; 2012 Mar; 66(3):343.e1-8; quiz 351-2. PubMed ID: 22342021
[TBL] [Abstract][Full Text] [Related]
28. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
[TBL] [Abstract][Full Text] [Related]
29. Generic drugs--safe, effective, and affordable.
Peters JR; Hixon DR; Conner DP; Davit BM; Catterson DM; Parise CM
Dermatol Ther; 2009; 22(3):229-40. PubMed ID: 19453347
[TBL] [Abstract][Full Text] [Related]
30. Predictors of Drug Shortages and Association with Generic Drug Prices: A Retrospective Cohort Study.
Dave CV; Pawar A; Fox ER; Brill G; Kesselheim AS
Value Health; 2018 Nov; 21(11):1286-1290. PubMed ID: 30442275
[TBL] [Abstract][Full Text] [Related]
31. An analysis of volumes, prices and pricing trends of the pediatric antiretroviral market in developing countries from 2004 to 2012.
Lee JSF; Sagaon Teyssier L; Dongmo Nguimfack B; Collins IJ; Lallemant M; Perriens J; Moatti JP
BMC Pediatr; 2016 Mar; 16():41. PubMed ID: 26979974
[TBL] [Abstract][Full Text] [Related]
32. Number of manufacturers and generic drug pricing from 2005 to 2017.
Hernandez I; Good CB; Gellad WF; Parekh N; He M; Shrank WH
Am J Manag Care; 2019 Jul; 25(7):348-352. PubMed ID: 31318508
[TBL] [Abstract][Full Text] [Related]
33. Is greater generic competition also linked to lower drug prices in South Korea?
Son KB
Health Econ Rev; 2020 Sep; 10(1):30. PubMed ID: 32930889
[TBL] [Abstract][Full Text] [Related]
34. Strategies That Delay Market Entry of Generic Drugs.
Vokinger KN; Kesselheim AS; Avorn J; Sarpatwari A
JAMA Intern Med; 2017 Nov; 177(11):1665-1669. PubMed ID: 28975217
[TBL] [Abstract][Full Text] [Related]
35. Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011.
Cheng N; Banerjee T; Qian J; Hansen RA
J Am Pharm Assoc (2003); 2017; 57(3):341-348. PubMed ID: 28400255
[TBL] [Abstract][Full Text] [Related]
36. Pharmaceutical pricing: an empirical study of market competition in Chinese hospitals.
Wu J; Xu J; Liu G; Wu J
Pharmacoeconomics; 2014 Mar; 32(3):293-303. PubMed ID: 24190661
[TBL] [Abstract][Full Text] [Related]
37. Are drug prices subject to creative destruction? Evidence from the US, 1997-2017.
Lichtenberg FR
Health Econ; 2021 Aug; 30(8):1910-1932. PubMed ID: 33987916
[TBL] [Abstract][Full Text] [Related]
38. Effect of Competition on Generic Drug Prices.
Nguyen NX; Sheingold SH; Tarazi W; Bosworth A
Appl Health Econ Health Policy; 2022 Mar; 20(2):243-253. PubMed ID: 34904207
[TBL] [Abstract][Full Text] [Related]
39. The state and consequences of dermatology drug prices in the United States.
Albrecht J; Lebwohl M; Asgari MM; Bennett DD; Cook A; Evans CC; Green LJ; Hodge JA; Kourosh AS; Maloney ME; Howard LM; Olsen EA; Rosenberg SP; Rubin A; Stough DB; Taylor SC; Brod BA
J Am Acad Dermatol; 2016 Sep; 75(3):603-605. PubMed ID: 27423978
[No Abstract] [Full Text] [Related]
40. Generic medicine pricing in Europe: current issues and future perspective.
Simoens S
J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
